## INTERNATIONAL SEARCH REPORT

International application No. PCT/JP2005/000786

.A.	CLASSIFICATION OF SUBJECT MATTER							
	$Int.Cl^7$	C12N15/09,	C12N5/06, C07K7/04, C07K14/715, C07K16/28,					
			A61P35/00, A61P37/04					
Acc	cording to Intern	national Patent Class	sification (IPC) or to both national classification and IPC					
B.	B. FIELDS SEARCHED							
Mir			assification system followed by classification symbols)					
	$Int.Cl^7$	C12N15/09,	C12N5/06, C07K7/04, C07K14/715, C07K16/28,					
		A61K39/00,	A61P35/00, A61P37/04					

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE/BIOSIS/WPI (DIALOG), CAPLUS/REGISTRY (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT Category\* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. $\frac{1,3-10}{2}$ Okugawa T. et al., A novel human HER2derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals, Eur.J.Immunol., 2000, Vol.30, pages 3338 to 3346 zum Buschenfelde C.M. et al., The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells, J.Immunol., 2001, Vol.167, pages 1712 to 1719

Further documents are listed in the continuation of Box C.	See patent family annex.		
* Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"E" earlier application or patent but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  "&" document member of the same patent family		
*P* document published prior to the international filing date but later than the priority date claimed			
Date of the actual completion of the international search 22 February, 2005 (22.02.05)	Date of mailing of the international search report 15 March, 2005 (15.03.05)		
Name and mailing address of the ISA  Japanese Patent Office	Authorized officer		
Facsimile No.	Telephone No		

## INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2005/000786

		PC1/UP2	005/000786
C (Continuation	). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relev	ant passages	Relevant to claim No.
Y A	Moscatello D.K. et al., A naturally occur mutant human epidermal growth factor rece as a target for peptide vaccine immunothe of tumors, Cancer Res., 1997, Vol.57, page 1419 to 1424	1,3-10	
Y A	Sato Y. et al., Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide, Cancer Sci., 2003, Vol.94, pages 802 to 808		<u>1,3-10</u> 2
$\frac{Y}{A}$	Mine T. et al., Immunological evaluation CTL precursor-oriented vaccines for advar lung cancer patients, Cancer Sci., 2003, Vol.94, pages 548 to 556		<u>1,3-10</u> 2
$\frac{Y}{A}$	Ullrich A. et al., Human epidermal growth factor receptor cDNA sequence and aberrar expression of the amplified gene in A431 epidermoid carcinoma cells, Nature, 1984, Vol.309, pages 418 to 425	nt	<u>1,3-10</u> 2
X	Baron A.T. et al., Monoclonal antibodies specific for peptide epitopes of the epic growth factor receptor's extracellular do Hybridoma, 1997, Vol.16, pages 259 to 271	omain,	10
X	JP 2002-525382 A (The Children's Medical Center Corp.), 13 August, 2002 (13.08.02), Full text (particularly, Sequence No.63) & WO 2000/18895 A1 & EP 1115847 A1 & US 2002/0160478 A1 & AU 9960590 A & CN 1319133 A		1,3-5
P,X	Shomura h. et al., Identification of epic growth factor receptor-derived peptides recognised by both cellular and humoral responses in HLA-A24+ non-small cell lung cancer patients, Eur.J.Cancer, 2004 July Vol.40, pages 1776 to 1786	immune	1-10